Status:
TERMINATED
A Study Evaluating The PF-03084014 In Combination With Docetaxel In Patients With Advanced Breast Cancer
Lead Sponsor:
Pfizer
Conditions:
Breast Cancer Metastatic
Eligibility:
FEMALE
18+ years
Phase:
PHASE1
Brief Summary
This study is aimed to determine the tolerability of the PF-03084014 plus docetaxel combination in patients with advanced breast cancer. Preliminary information about the efficacy of the combination w...
Eligibility Criteria
Inclusion
- Diagnosis of breast cancer with evidence of a) metastatic or b) locally recurrent/advanced disease.
Exclusion
- Prior treatment with a gamma secretase inhibitors or other Notch signaling inhibitors.
Key Trial Info
Start Date :
November 4 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 24 2015
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT01876251
Start Date
November 4 2013
End Date
December 24 2015
Last Update
March 15 2019
Active Locations (16)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35233
2
University of Alabama at Birmingham, IDS Pharmacy
Birmingham, Alabama, United States, 35249
3
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35249
4
Stanford Cancer Institute
Stanford, California, United States, 94305